Special Issue

Stereotactic Radiosurgery for Brain Tumors

Message from the Guest Editors

Stereotactic radiosurgery (SRS) is the use of a high dose of radiation, stereotactically directed to an intracranial region of interest. This allows for non-surgical treatment of intracranial pathologies, which significantly decreases the risk of morbidity. There are currently a number of different delivery methods of SRS, including linear accelerators, Gamma or Cyber Knife units, and charged particle methods. Radiosurgery is currently used in the treatment of brain metastases, meningiomas, vestibular schwannomas, sellar and suprasellar lesions, and arteriovenous malformations. Moreover, SRS is widely used to treat functional conditions, such as trigeminal neuralgia and intractable tremor. Researchers and clinicians employing SRS in the daily practice are invited to submit manuscripts regarding technical as well as clinical issues. We look forward to receiving your contributions.

Guest Editors

Dr. Dante Amelio

Dr. Piera Navarria

Dr. Giuseppe Minniti

Deadline for manuscript submissions closed (15 February 2025)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 4.9 Indexed in PubMed



mdpi.com/si/183092

Current Oncology Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 currentoncology@mdpi.com

mdpi.com/journal/ curroncol



¢Ø

Current Oncology

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 4.9 Indexed in PubMed



curroncol



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

 College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada
Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)